Overview

Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

Here we are going to find a method by using available multiple drugs including angiogenesis medicine - Endostar to treat lung cancer patients who acquired resistence from EGFR-TKI but have responsed to it before.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Peking University Third Hospital

Treatments:

Endostatins